WO2026021930A2 - Immunisation contre le streptocoque du groupe a (gas) - Google Patents

Immunisation contre le streptocoque du groupe a (gas)

Info

Publication number
WO2026021930A2
WO2026021930A2 PCT/EP2025/070101 EP2025070101W WO2026021930A2 WO 2026021930 A2 WO2026021930 A2 WO 2026021930A2 EP 2025070101 W EP2025070101 W EP 2025070101W WO 2026021930 A2 WO2026021930 A2 WO 2026021930A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
evs
use according
protein
spy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/070101
Other languages
English (en)
Inventor
Birgitta HENRIQUES NORMARK
Staffan Normark
Meztlli Ofelia GAYTÁN ENRÍQUEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2026021930A2 publication Critical patent/WO2026021930A2/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to means and methods for inducing adaptive immune response against group A streptococcus.
  • GAS Group A Streptococcus
  • strep throat pharyngitis
  • impetigo invasive diseases
  • necrotizing fasciitis flesh-eating disease
  • streptococcal toxic shock syndrome a condition such as pharyngitis (strep throat) and impetigo
  • invasive diseases include necrotizing fasciitis (flesh-eating disease) and streptococcal toxic shock syndrome.
  • Rheumatic heart disease a complication of rheumatic fever which itself is a complication of untreated strep throat, is a significant contributor to the global disease burden of GAS. It is estimated that there are over 30 million cases of RHD worldwide, resulting in about 300,000 deaths annually.
  • GAS infections depends on the severity and type of infection.
  • non-invasive diseases like strep throat and impetigo
  • oral antibiotics such as penicillin or amoxicillin are typically prescribed.
  • Invasive GAS diseases require more aggressive treatment, often involving intravenous antibiotics and sometimes surgery.
  • surgical debridement of the infected tissue is usually necessary.
  • long-term antibiotic prophylaxis is recommended to prevent recurrent GAS infections and further damage to the heart valves.
  • GAS GAS is characterized by a high degree of strain diversity. There are over 200 known serotypes of GAS, each with different M proteins, the major virulence factor of the bacteria. This diversity makes it difficult to develop a single vaccine that can provide broad protection against all strains.
  • M proteins M proteins
  • autoimmune reactions Some of the proteins in GAS are similar to human proteins, and there is a concern that a vaccine could trigger an immune response not only against the bacteria but also against the body's own tissues. This is particularly relevant given the link between GAS infections and autoimmune diseases such as rheumatic heart disease.
  • GAS Group A Streptococcus
  • EVs extracellular vesicles
  • macromolecules such as RNAs, proteins and lipids
  • an object of the present invention is the provision of alternative or improved means and methods for inducing adaptive immune response against GAS.
  • extracellular vesicles refer to membrane-derived vesicles released by bacteria, in particular Streptococcus pyogenes, such as strain 5448AP.
  • the EVs can carry many different types of macromolecules, virulence factors and proteins, both soluble and membrane associated.
  • antigen refers to structures to which antibodies generated by the adaptive immune system of vertebrates specifically bind, or to which specific T-cell responses are elicited. Antigens are often proteins, peptides or polysaccharides (sometimes containing a lipid moiety). In the context of vaccines, an antigen is an ingredient in a vaccine against which a specific antibody or T-cell response is intended to be elicited in the host to which the vaccine is administered. Some vaccines contain several antigens. In the vaccine context, a vaccine antigen generally bears a structural resemblance to a pathogen antigen present in a pathogen against which the vaccine is intended to be used.
  • a vaccine antigen may for example be a fragment or a modified version of the pathogen antigen, or a complete pathogen antigen presented in a non-pathogenic form e.g., as an inactivated pathogen or a recombinant protein produced in a suitable host.
  • adjuvant refers to a component added to vaccines and other immunogenic compositions that increases the effectiveness of the immune response to the antigen present in the vaccines or other immunogenic composition.
  • Group A Streptococcus refers to the bacterium Streptococcus pyogenes.
  • MtsA refers to Streptococcus pyogenes iron ABC transporter substrate-binding lipoprotein which is part of the ATP-binding cassette (ABC) transport system MtsABC involved in iron import (Uniprot entry: P0A4G4).
  • a reference sequence from Streptococcus pyogenes is presented in SEQ ID NO 1.
  • the MtsA protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 1, or an immunologically effective fragment thereof.
  • SPy_1228 refers to a Streptococcus pyogenes plasma membrane lipoprotein of unknown function (Uniprot entry: Q99ZH4).
  • a reference sequence from Streptococcus pyogenes is presented in SEQ ID NO 2.
  • BMP is used interchangeably herein.
  • the SPy_1228 protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 2, or an immunologically effective fragment thereof.
  • PrsAl and PrsA2 refer to Streptococcus pyogenes parvulin-type peptidyl-prolyl isomerase 1 and 2, respectively (Uniprot entries P60811 and P60812). These foldase proteins play a major role in protein secretion by helping the post-translocational extracellular folding of several secreted proteins. These proteins have been implicated as virulence factors and play a role in biofilm formation, host adherence, and infection-induced cytotoxicity. Reference sequences from Streptococcus pyogenes are presented in SEQ ID NO: 3 (PrsAl) and SEQ ID NO: 4 (PrsA2).
  • the PrsAl protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 3, or an immunologically effective fragment thereof.
  • the PrsA2 protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 4, or an immunologically effective fragment thereof.
  • GlnP refers to Streptococcus pyogenes ABC transmembrane type-1 domain-containing protein (Uniprot entry: Q99ZA4).
  • a reference sequence from Streptococcus pyogenes is presented in SEQ ID NO 5.
  • the GlnP protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 5, or an immunologically effective fragment thereof.
  • MalX is a maltose/maltodextrin-binding protein required for the uptake of maltose (a disaccharide of glucose) and maltodextrin (glucose oligosaccharides) from the host environment.
  • Streptococcal MalX homologues are present in most streptococcal species including Streptococcus pyogenes (Uniprot Q99ZB1), Streptococcus pneumoniae, Streptococcus suis, Streptococcus e ui, Streptococcus mitis, and Streptococcus pseudopneumoniae.
  • MalX is a lipoprotein and as such attached to a lipid (diacylglycerol) in the outer leaflet of the plasma membrane through covalent thioester bond linkage via its N- terminal cysteine residue of the mature protein.
  • lipid diacylglycerol
  • SEQ ID NO 6 A reference sequence from Streptococcus pyogenes is presented in SEQ ID NO 6.
  • the MalX protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 6, or an immunologically effective fragment thereof.
  • SPy_0319 refers to a poorly characterized protein classified as part of ABC-type transport system and periplasmic component/surface antigen (Uniprot entry Q9A1E4). It shares sequence similarity with lipoproteins involved in the transport of methionine. A reference sequence from Streptococcus pyogenes is presented in SEQ ID NO 7. The terms NIpA and MetQ are used synonymously herein to refer to the same protein.
  • the SPy_0319 protein may comprise a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, yet more preferably at least 95%, even more preferably at least 98%, most preferably complete sequence identity to SEQ ID NO: 7, or an immunologically effective fragment thereof.
  • protective immunity in the present context refers to immunization measures resulting in any degree of reduction in the likelihood of developing the condition for which the protective immunity is relevant, including a minor, substantial or major reduction in likelihood of developing the condition as well as total prevention.
  • the degree of likelihood reduction is at least a minor reduction.
  • sequence identity expressed in percentage is defined as the value determined by comparing two optimally aligned sequences over a comparison window, wherein a portion of the sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
  • the percentage is calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • the comparison window is the entire length of the sequence being referred to.
  • isolated when used herein in reference to a protein, refers to a protein that has been substantially separated, purified, or enriched from its natural environment, such as a whole cell, whole cell extract, or other complex biological matrix in which it is naturally found.
  • an "isolated” protein exists in a form that is significantly more concentrated or pure than in its native state, having undergone one or more processes such as enrichment, purification, or recombinant production.
  • an isolated protein may be obtained through techniques including, but not limited to, chromatography, centrifugation, precipitation, or recombinant expression in a host cell followed by purification, resulting in a preparation where the protein may be substantially free of other cellular components, contaminants, or biomolecules present in the original cellular or extract context.
  • isolated does not encompass a protein as it exists in an intact whole cell or in a crude whole cell extract where it remains in its naturally occurring concentration and environment without deliberate separation, concentration or enrichment.
  • isolated when used in reference to extracellular vesicles (EVs) produced by bacterial cells, refers to EVs that have been substantially separated, purified, or enriched from their natural environment, such as the bacterial cells that produce them, the surrounding culture medium, or crude bacterial cell extracts.
  • An "isolated" extracellular vesicle exists in a form that is significantly more concentrated or purified than in its native state, having undergone one or more processes such as enrichment, purification, or controlled production to separate the EVs from other cellular components, debris, or extracellular matrix materials. Such processes may include, but are not limited to, centrifugation, ultrafiltration, size-exclusion chromatography, or affinity-based separation techniques.
  • isolated does not encompass extracellular vesicles as they exist in their naturally occurring state within a bacterial culture, associated with the surface of bacterial cells, or in an unprocessed bacterial cell supernatant where they remain in their native concentration and environment without deliberate separation, concentration or enrichment.
  • FIG. 1 Characterization of GAS EVs. a) Cryo-EM image of GAS EVs isolated from liquid media, b) GAS EV size distribution determined by dynamic light scattering.
  • FIG. 1 GAS-specific IgG and IgA response in sera and nasal wash, a) Immunization scheme. 5-week-old male C57BL/6 mice were immunized intranasally with 50 pl of GAS EVs (10 pg) formulated with aluminium hydroxide (alum, lOmg/ml). The control group was immunized with alum in PBS. b) GAS-specific IgG and IgA levels from serum (left) and nasal wash (right), respectively, were analyzed by whole bacteria ELISA. Bars represent mean + standard error of the mean (SEM) of three independent experiments. Each symbol represents data from an individual mouse. Significance was determined by two-tailed unpaired t-test (IgG's) or Mann-Whitney test (IgA's). **, P ⁇ 0.01; ***, P ⁇ 10.001.
  • FIG. 3 Intranasal immunization with GAS EVs enhances recruitment of activated CD4 + T cells to the lung. Mice were immunized as described in Figure 2a. Lung samples were collected 7 days after the last immunization. The percentage and total number of CD4 + T cells (upper panels) and CD44 + CD4 + T cells (lower panels) was determined by flow cytometry. Bars represent mean + SEM of two independent experiments. Each symbol represents data from an individual mouse. Significance was determined by two-tailed unpaired t-test (% and # of CD44 + CD4 + T cells) or Mann-Whitney test (% and # of CD4 + T cells). ***, P ⁇ 0.001; ****, P ⁇ 0.001. Figure 4. Intranasal immunization with GAS EVs elicits Thl7 and Thl responses in the lung.
  • mice were immunized as described in Figure 2a. Lung samples were collected 7 days after the last immunization and stained for flow cytometry analysis (a,b,d and e) or cultured ex vivo to measure cytokines response to antigen stimulation (c and f). a) Percentage (%) and total number (#) of I L-17 + CD44 + CD4 + T cells, b) % of RORyT + CD44 + CD4 + T cells, d) % and # of I FNy + CD44 + CD4 + T cells, e) % of T-bet + CD44 + CD4 + T cells. Lung cells were cultured ex vivo and stimulated with GAS EVs or media for 72h.
  • Thl7-specific IL17A c
  • Thl-specific I FNy f
  • cytokines cytokines into the culture supernatant was measured by ELISA. Data are normalized to media stimulation controls. Bars represent mean + SEM of two (flow cytometry) or three (cytokines) independent experiments. Each symbol represents data from an individual mouse. Significance was determined by two-tailed unpaired t-test (% and
  • FIG. 6 Identification of immunostimulatory antigens on GAS EVs.
  • FIG. 7 Identification of immunostimulatory antigens on GAS EVs. Isogenic mutants in each of the antigens were generated. The cell lysates of these mutants were probed by western blot using sera from immunized mice (left panel). GAPDH was used as a loading control. Right panel shows IgG binding to heat-inactivated GAS AP WT or an isogenic mutant lacking SPy_1228, MtsA and PrsA2 (GAS AP Aspy_1228 AmtsA, AprsA2), as tested by wholebacteria ELISA. The total IgG binding what slightly reduced for the mutant compared to the wild-type strain. Bars represent mean + SEM. Statistical comparisons were made using Mann Whitney test (*, P 0.05; **, P ⁇ 0.01; ***, P ⁇ 0.001, ****, P ⁇ 0.001).
  • FIG. 8 IL-17A response to antigen stimulation.
  • Lung cells (a) and splenocytes (b) from mice immunized with alum or GAS EVs (formulated with alum) were collected 1 week after the second immunization.
  • Cells were cultured ex vivo and stimulated with 1 pg of recombinantly expressed proteins (MtsA, BMP (SPy_1228), PrsAl, PrsA2, MetQ (SPy_0319), GlnP or MalX) or media for 72h.
  • MtsA, BMP (SPy_1228), PrsAl, PrsA2, MetQ (SPy_0319), GlnP or MalX recombinantly expressed proteins
  • the concentration of IL-17A in culture supernatants was measured by ELISA.
  • Data are normalized to media stimulation controls and represented as mean + SEM of 2 independent experiments. Statistical comparisons were made using Mann Whitney test. **, P ⁇ 0.01;
  • FIG. 9 IFNy response to antigen stimulation.
  • Lung cells (a) and splenocytes (b) from mice immunized with alum or GAS EVs (formulated with alum) were collected 1 week after the second immunization.
  • Cells were cultured ex vivo and stimulated with 1 pg of recombinantly expressed proteins (MtsA, BMP, PrsAl, PrsA2, MetQ (SPy_0319), GlnP or MalX) or media for 72h.
  • the concentration of IFNy in culture supernatants was measured by ELISA. Data are normalized to media stimulation controls and represented as mean + SEM of 2 independent experiments. Statistical comparisons were made using Mann Whitney test. ***, P ⁇ 0.001.
  • FIG. 10 Antigens identified in GAS EVs are conserved across GAS strains, a) Western blot analysis of GAS EVs and bacterial lysates of different invasive GAS isolates (M-type is indicated in brackets). Samples were probed with sera from GAS EVs-immunized mice (top panel) or anti-GAPDH as a loading control (bottom panel), b) IgG binding to different GAS strains was analyzed by whole-cell ELISA. Plates were coated with different invasive GAS strains, covering a range of M-types, and probed with sera from mice vaccinated with alum (light grey circles) or GAS EVs (blue circles). Bars represent mean + SEM of four independent experiments.
  • mice were immunized with adjuvant (AS02-IS ke), GAS EVs (30 ug formulated with adjuvant) or recombinant proteins (5 ug of MalX, PrsA2, PrsAl, SPy_1228, GlnP, MtsA or NIpA (SPy_0319), also formulated with AS02-like adjuvant - denoted "rProt"). Two doses were delivered subcutaneously 2 weeks apart. Two weeks after the second immunization, sera were collected and measured for antigen specific IgGs.
  • adjuvant AS02-IS ke
  • GAS EVs (30 ug formulated with adjuvant)
  • recombinant proteins (5 ug of MalX, PrsA2, PrsAl, SPy_1228, GlnP, MtsA or NIpA (SPy_0319)
  • rProt AS02-like adjuvant
  • Antibody levels for MtsA, SPy_1228, PrsAl, PrsA2, NIpA (SPy_0319), GlnP and MalX were measured by ELISA. Bars represent mean + SEM. Statistical comparisons were made using a two-tailed unpaired t-test. ***, P ⁇ 0.001; ****, p ⁇ 0.001. Immunization with recombinant proteins resulted in high IgG levels (slightly higher than immunization with EVs) for PrsA2, PrsAl, Spy_1228 and GlnP. For MtsA and NIpA, immunization with EVs resulted in higher titers than recombinant proteins. For MalX, immunization with protein generated a robust IgG response, whereas the immunization with EVs resulted in poor immune response.
  • the present invention relates to the following items.
  • the subject matter disclosed in the items below should be regarded disclosed in the same manner as if the subject matter were disclosed in patent claims.
  • a composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) and a pharmaceutically acceptable vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject.
  • EVs isolated Streptococcus pyogenes extracellular vesicles
  • GAS group A streptococcus
  • composition comprising isolated 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP, SPy_0319 and/or MalX for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject.
  • GAS group A streptococcus
  • composition for use according to item 1 or 2 wherein the immune response is a T-cell response, preferably a Thl7-response.
  • the immune response is an IgG response, IgA response, or a combined IgG and IgA response.
  • composition for use according to any of the preceding items, wherein the composition further comprises an adjuvant.
  • compositions for use according to any of the preceding items wherein the composition further comprises an adjuvant selected from the group consisting of (i) aluminium hydroxide; (ii) aluminium phosphate; (iii) a lipid-based substance such as squalene or quillaja saponin; and (iv) a protein or other immune stimulating component from a microbe such as diphtheria (preferably CRM), cholera (preferably choleratoxoid CTB or mmCT) or Escherichia coli (preferably non-toxic heat-labile toxin such as LTK63 or dmLT).
  • an adjuvant selected from the group consisting of (i) aluminium hydroxide; (ii) aluminium phosphate; (iii) a lipid-based substance such as squalene or quillaja saponin; and (iv) a protein or other immune stimulating component from a microbe such as diphtheria (preferably CRM), cholera (preferably choleratoxo
  • composition for use according to any of the preceding items, wherein the composition comprises EVs in an amount of at least 1 pg/ml, preferably at least 5 pg/ml, more preferably at least 10 pg/ml, even more preferably 25 pg/ml, still more preferably 50 pg/ml, yet more preferably 75 pg/ml, most preferably at least 100 pg/ml.
  • pyogenes protein MtsA preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • pyogenes protein SPy_1228 preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • pyogenes protein PrsAl preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • pyogenes protein PrsA2 preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • pyogenes protein GlnP preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • pyogenes protein SPy_0319 preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the composition for use according to item 1 or 8, or any item dependent thereon, wherein the EVs comprise the 5.
  • composition for use according to any of the preceding items wherein the composition comprises the 5. pyogenes protein MtsA at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition for use according to any of the preceding items wherein the composition comprises the 5. pyogenes protein SPy_1228 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition for use according to any of the preceding items wherein the composition comprises the 5.
  • pyogenes protein PrsAl at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml
  • composition for use according to any of the preceding items wherein the composition comprises the 5. pyogenes protein PrsA2 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition for use according to any of the preceding items, wherein the composition comprises the 5.
  • pyogenes protein GlnP at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition for use according to any of the preceding items, wherein the composition comprises the 5.
  • pyogenes protein SPy_0319 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition for use according to any of the preceding items, wherein the composition comprises the 5.
  • pyogenes protein MalX at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition for use according to any of the preceding items, wherein the composition comprises each of the 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP and SPy_0319 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • compositions for use according to any of the preceding items wherein the composition is for use by injection (including intramuscular, intracutaneous, subcutaneous, intravenous), buccal administration, oral administration or intranasal administration.
  • compositions for use according to any of the preceding items wherein the composition further comprises one or more group A streptococcus antigen(s) in addition to MtsA, SPy_1228, PrsAl, PrsA2, GlnP, MalX and/or SPy_0319. 29.
  • the composition is essentially free of Streptococcus pyogenes whole cells.
  • composition for use according to any of the preceding items, wherein the composition is an immunogenic composition.
  • composition for use according to any of the preceding items for use in a method for inducing protective immunity in a subject against a GAS infection selected from streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever, and post-streptococcal glomerulonephritis.
  • a GAS infection selected from streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever, and post-streptococcal glomerulonephritis.
  • mice Streptococcus pyogenes
  • GAS Streptococcus pyogenes
  • EVs extracellular vesicles
  • Main immunostimulatory proteins were identified in Example 5.
  • Thl7 immunological memory recall was also demonstrated (Example 6).
  • the immunostimulatory antigens identified in GAS EVs were shown to be conserved across different M-types (Example 7).
  • Using recombinant versions of the identified immunostimulatory GAS-proteins for immunization was demonstrated in Example 8.
  • the present invention provides a composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) and a pharmaceutically acceptable vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject, preferably a human.
  • EVs may be suspended in the vehicle.
  • the EVs contain multiple proteins acting as antigens, ensuring a broad host exposure to relevant GAS antigens increasing the odds of protection against multiple strains.
  • the EVs also contain bacterial components (both protein and non-protein) that may trigger host immune responses leading to more robust adaptive immune response (thus providing adjuvant-like effects).
  • the present invention provides a composition comprising isolated 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP, SPy_0319 and/or MalX for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject, preferably a human.
  • GAS group A streptococcus
  • Isolated proteins may be advantageous in that they can be readily produced in large quantities in industrial processes (e.g. recombinantly) and may therefore be most cost- effective.
  • the relative amounts of the antigens are convenient to tailor when combining different isolated proteins in a composition.
  • the EVs according to the first aspect may be combined with one or more isolated proteins of the second aspect, as will be explained in more detail below. Such combination allows convenient adjustment of the relative amounts of the antigens.
  • pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP, SPy_0319 and/or MalX may be collectively referred to as "the antigen(s)" herein.
  • the immune response may be a T-cell response, preferably a Thl7-response.
  • the immune response may alternatively or additionally be an IgG response, IgA response, or a combined IgG and IgA response.
  • composition of the first or the second aspect may comprise EVs in an amount of at least 1 pg/ml, preferably at least 5 pg/ml, more preferably at least 10 pg/ml, even more preferably 25 pg/ml, still more preferably 50 pg/ml, yet more preferably 75 pg/ml, most preferably at least 100 pg/ml.
  • the composition of the first or the second aspect is free, essentially free or substantially devoid of Streptococcus pyogenes whole cells (live or killed). In certain embodiments, the composition contains less than 10 3 Streptococcus pyogenes whole cells per ml, more preferably less than 10 2 cells/ml, most preferably less than 10 cells/ml.
  • the composition is free, essentially free or substantially devoid of Streptococcus pyogenes whole cell lysate.
  • the composition contains unfractionated whole cell lysate components corresponding to the constituents of less than 10 5 Streptococcus pyogenes whole cells per ml, more preferably less than 10 3 /ml, most preferably less than 10 2 /ml.
  • the composition of the first or the second aspect is preferably not an unfractionated Streptococcus pyogenes lysate.
  • composition of the first or the second aspect may be formulated as an immunogenic composition or as a vaccine.
  • the aforementioned EVs may be obtained as follows. EVs are produced culturing 5. pyogenes (e.g. strain 5448 AP) to late log phase in Todd Hewitt liquid media. Bacterial culture is centrifuged and filtered to obtain cell-free supernatant. Cell-free supernatant is concentrated by tangential flow filtration followed by ultracentrifugation. EVs are purified by density gradient and washed with PBS, using subsequent steps of ultracentrifugation. Finally, EVs are resuspended in a vehicle (see Example 1).
  • pyogenes e.g. strain 5448 AP
  • Bacterial culture is centrifuged and filtered to obtain cell-free supernatant. Cell-free supernatant is concentrated by tangential flow filtration followed by ultracentrifugation.
  • EVs are purified by density gradient and washed with PBS, using subsequent steps of ultracentrifugation. Finally, EVs are
  • composition of the first or the second aspect may further comprise an adjuvant, many of which are known in the art.
  • the adjuvant may be selected from aluminium hydroxide, aluminium phosphate, a lipid-based substance such as squalene or quillaja saponin, an immune-stimulating component or a protein from a microbe such as diphtheria (preferably CRM), cholera (preferably choleratoxoid CTB or mmCT) or Escherichia coli (preferably nontoxic heat-labile toxin such as LTK63 or dmLT).
  • a microbe such as diphtheria (preferably CRM), cholera (preferably choleratoxoid CTB or mmCT) or Escherichia coli (preferably nontoxic heat-labile toxin such as LTK63 or dmLT).
  • composition of the first or the second aspect may comprise immunogenic amount(s) of the 5.
  • the aforementioned EVs may comprise immunogenic amount(s) of the 5.
  • the amount(s) may be according to an embodiment in Table 1.
  • the sign "+" denotes >0.001 pg/mg, preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the sign "+" denotes a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the EVs may comprise one or more of the 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP and/or SPy_O319 at the level of >0.001 pg/mg, preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5.
  • pyogenes protein MtsA preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5.
  • pyogenes protein SPy_1228 preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5.
  • pyogenes protein PrsAl preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5. pyogenes protein PrsA2, preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5. pyogenes protein GlnP, preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5. pyogenes protein SPy_0319, preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the EVs may comprise an immunogenic amount of the 5. pyogenes protein MalX, preferably at the level of >0.001 pg/mg, more preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the composition of the first or the second aspect may comprise the 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP and/or SPy_0319 associated with the EVs at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • Associated in this context may refer to covalent association, ionic association, lipid-anchoring or transmembrane configuration with the EVs.
  • the 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP, SPy_0319 and/or MalX may additionally be present as non-EV associated form in the composition of the first aspect.
  • purified recombinant or purified proteins can be added to the composition of the first aspect.
  • the concentrations specified below represent the total amount of the protein present in the composition, whether EV associated or not.
  • the composition of the first or the second aspect may comprise of the 5. pyogenes protein MtsA at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the composition of the first or the second aspect may comprise the 5. pyogenes protein SPy_1228 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the composition of the first or the second aspect may comprise the 5. pyogenes protein PrsAl at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the composition of the first or the second aspect may comprise the 5. pyogenes protein PrsA2 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the composition of the first or the second aspect may comprise the 5. pyogenes protein GlnP at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the composition of the first or the second aspect may comprise the 5. pyogenes protein SPy_0319 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • the composition of the first or the second aspect may comprise the 5.
  • pyogenes protein MalX at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition of the first or the second aspect may comprise each of the 5. pyogenes protein(s) MtsA, SPy_1228, PrsAl, PrsA2, GlnP and SPy_0319 at a concentration of at least 0.0001 pg/ml, or in an increasing order of preference: at least 0.005 pg/ml, at least 0.001 pg/ml, at least 0.01 pg/ml, at least 0.03 pg/ml, at least 0.05 pg/ml, at least 0.08 pg/ml, at least 0.1 pg/ml, at least 0.3 pg/ml, at least 0.5 pg/ml, at least 0.8 pg/ml or at least 1 pg/ml.
  • composition of the first or the second aspect may further comprise one or more group A streptococcus antigen(s) in addition to MtsA, SPy_1228, PrsAl, PrsA2, GlnP, MalX and/or SPy_0319.
  • the EVs may be from EVs released by 5.
  • the EVs may have a diameter in the range of about 40 to about 400 nm as determined by dynamic light scattering or electron microscopy.
  • composition of the first or the second aspect may be provided as a unit dose, which herein refers to a dose to be administered to an individual for eliciting an adaptive immune response against GAS.
  • a unit dose refers to a dose to be administered to an individual for eliciting an adaptive immune response against GAS.
  • the amounts of components in a unit dose may vary depending on the subject to be immunized, for instance children may receive lower doses than adults.
  • a unit dose may be provided in liquid form or in dried (e.g. lyophilized) form that is reconstituted prior to administration.
  • the volume administered to an individual is dictated practical constraints but would typically be in the order of 0.1-0.5 ml.
  • an immunogenic composition of the first aspect as a unit dose, containing aforementioned EVs and optionally additional antigens and components as disclosed for the composition of the first aspect.
  • the amounts of EVs and optional additional antigens in the unit dose may correspond to 0.5 ml of a composition of the first aspect.
  • a unit dose may contain the 5.
  • pyogenes protein MtsA at a concentration of at least 0.00005 pg, or in an increasing order of preference: at least 0.0025 pg, at least 0.0005 pg, at least 0.005 pg, at least 0.015 pg, at least 0.025 pg, at least 0.04 pg, at least 0.05 pg, at least 0.15 pg, at least 0.25 pg, at least 0.4 pg or at least 0.5 pg.
  • SPy_1228, PrsAl, PrsA2, SPy_0319, MalX and/or GlnP based on the disclosure of the first aspect, mutatis mutandis.
  • composition of the first aspect as a unit dose may contain the antigens as disclosed in Table 1, wherein "+” denotes >0.001 pg/mg, preferably >0.01 pg/mg, even more preferably >0.02 pg/mg, yet more preferably >0.05 pg/mg, most preferably >0.1 pg/mg of the total protein in the EVs.
  • the unit dose may comprise EVs in an amount of at least 0.5 pg, preferably at least 2.5 pg, more preferably at least 5 pg, even more preferably 12.5 pg, still more preferably 25 pg, yet more preferably 37.5 pg, most preferably at least 50 pg.
  • a unit dose of the first aspect may contain the antigens as disclosed in Table 1 wherein "+" denotes presence of the antigen an amount of at least 0.00005 pg, or in an increasing order of preference: at least 0.0025 pg, at least 0.0005 pg, at least 0.005 pg, at least 0.015 pg, at least 0.025 pg, at least 0.04 pg, at least 0.05 pg, at least 0.15 pg, at least 0.25 pg, at least 0.4 pg or at least 0.5 pg.
  • the amounts refer to total amount present and includes both EVs- associated and non-associated protein.
  • an immunogenic composition of the second aspect as a unit dose, containing components as disclosed for the composition of the second aspect.
  • the amounts of the antigen(s) in the unit dose may correspond to 0.5 ml of a composition of the second aspect.
  • a unit dose may contain the 5. pyogenes protein MtsA at an amount of at least 0.00005 pg, or in an increasing order of preference: at least 0.0025 pg, at least 0.0005 pg, at least 0.005 pg, at least 0.015 pg, at least 0.025 pg, at least 0.04 pg, at least 0.05 pg, at least 0.15 pg, at least 0.25 pg, at least 0.4 pg or at least 0.5 pg.
  • a unit dose of the second aspect may contain the antigens as disclosed in Table 1, wherein "+” denotes presence of the antigen an amount of at least 0.00005 pg, or in an increasing order of preference: at least 0.0025 pg, at least 0.0005 pg, at least 0.005 pg, at least 0.015 pg, at least 0.025 pg, at least 0.04 pg, at least 0.05 pg, at least 0.15 pg, at least 0.25 pg, at least 0.4 pg or at least 0.5 pg.
  • the amounts refer to total amount present and includes both EVs-associated and non-associated protein.
  • composition of the first or the second aspect may be for use by injection (including intramuscular, intracutaneous, subcutaneous, intravenous), buccal administration, oral administration or intranasal administration.
  • composition of the first or the second aspect may be for use in a method for inducing protective immunity in a subject against a GAS infection.
  • composition of the first or the second aspect may be for use in a method for inducing protective immunity in a subject against colonization by GAS.
  • composition of the first or the second aspect may be for use in a method for inducing protective immunity in a subject against a GAS infection selected from streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and poststreptococcal glomerulonephritis.
  • a GAS infection selected from streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and poststreptococcal glomerulonephritis.
  • composition of the first or the second aspect may be for use in a method involving a single administration, two administrations, three administrations or more than three administrations to the subject.
  • the administrations can be separated in time by at least 7 days, at least 14 days, at least 28 days, at least two months, at least 6 months, 7-14 days, 7- 28 days, 28 days to two months, 28 days to 6 months or any other combination of aforementioned times.
  • Multiple administrations may be performed using the same mode of administration. Multiple administrations may be performed using the same composition.
  • Example 1 Characterization of S. pyogenes-derived extracellular vesicles.
  • pyogenes strain 5448 AP (GAS EVs) were purified from cell-free supernatant. 5. pyogenes strain 5448 AP was grown to an ODeoo 0.6 in Todd Hewitt, bacterial culture was centrifugated and filtrated to obtain cell-free supernatant. Cell-free supernatant was concentrated by tangential flow filtration followed by ultracentrifugation. GAS EVs were purified by density gradient and washed using ultracentrifugation. GAS EVS were visualized by cryo-electron microscopy (Cryo-EM).
  • GAS EVs appear as single membrane vesicles of different sizes (Fig 1A), with no evidence for the presence of a cell-wall. As determined by dynamic light scattering (DLS), the size distribution of GAS EVS ranges from 40 to 400 nm in diameter, with a median size of 145 nm (Fig IB). GAS EVs are loaded with ⁇ 700 proteins, as determined by mass-spectrometry analysis (data not shown). The cargo of these vesicles includes surface antigens, virulence factors and other proteins.
  • DLS dynamic light scattering
  • Example 2 Intranasal immunization with GAS EVs generates GAS-specific antibodies.
  • mice Male C57BL/6 mice were immunized intranasally with 50uL of GAS EVs (10 ug) formulated with aluminum hydroxide (alum, 10 mg/ml).
  • the control group was immunized with PBS and adjuvant alone (alum, lOmg/ml).
  • Two immunizations, 14 days apart, were delivered intranasally (Figure 2A). Twenty-one days after the primary immunization, sera and nasal washes were collected and used to measure GAS-specific IgG and IgA levels, respectively.
  • the levels of GAS-specific IgG in sera were significantly increased in the GAS EVs-immunized group as compared to the control group.
  • Example 3 Intranasal immunization with GAS EVs induces Thl7 and Thl responses in lung.
  • Previous reports have shown that Thl7 and Thl cell-responses are important for protection against GAS infections ( Carey, A. J. et al. Interleukin-17A contributes to the control of streptococcus pyogenes colonization and inflammation of the female genital tract. Sci. Rep. 6, 26836 (2016). Christensen, D., Mortensen, R., Rosenkrands, I., Dietrich, J. & Andersen, P. Vaccine-induced Thl7 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal. Immunol.
  • Activated CD4 + T cells recruited to the lung are predominantly Thl7 cells as evidenced by the significant increase in IL-17 production and RORyT expression following non-specific restimulation with PMA and ionomycin (Figure 4a-b).
  • a significant increase in I FNy production (but not T-bet expression) from CD4 + T cells in the lung following GAS EVs immunization was also observed ( Figure 4d-e), suggesting a small, but significant Thl response.
  • secreted IL-17A and I FNy in cell culture supernatants of lung cells stimulated ex vivo with GAS EVs were measured by ELISA. Stimulation of lung cells from GAS EVs-immunized mice induced a significant increase in the secretion of IL-17A and IFNy as compared to PBS-immunized mice ( Figure 4c and 4f).
  • Example 4 Intranasal immunization with GAS EVs induces systemic Thl7 response
  • intranasal immunization with GAS EVs also induced a systemic Thl7 response as evidenced by the significant increase in the % of I L-17 + activated T cells in spleen (Figure 5a) and increased secretion of IL-17A by splenocytes stimulated ex vivo with GAS EVs (Figure 5c). Although there was no increase in IFNy production from CD4 + T cells ( Figure 5b), a significant increase in IFNy secretion by splenocytes stimulated with GAS EVs was observed ( Figure 3d). These results indicate that immunization with GAS EVs can elicit the systemic activation of CD4 + T cells and the induction of a Thl7 response.
  • Example 5 Identification of immunostimulatory antigens on GAS EVs.
  • Examples 2-4 demonstrated that immunization with EVs elicited a humoral and cellular response in mice.
  • the inventors proceeded to identify the antigens responsible for these immunostimulatory properties of GAS EVs.
  • the identity of these immunoreactive antigens was determined by coimmunoprecipitation coupled to mass spectrometry ( Figure 6a, table to the right).
  • MtsA is the substrate binding lipoprotein of the ABC transporter responsible for iron/manganese transport (Janulczyk R, Ricci S, Bjbrck L.
  • MtsABC is important for manganese and iron transport, oxidative stress resistance, and virulence of Streptococcus pyogenes. Infect Immun. 2003 May;71(5):2656-64. doi:
  • SPy_1228 and GlnP have not been characterized in GAS but share sequence similarity with the substrate binding lipoprotein of ribonucleoside ABC transporters (BMP) [4] and the glutamine permease GlnP, respectively [5], SPy_0319 has not been characterized in GAS but has been classified in silico as an ABC-type transport system, periplasmic component/surface antigen based on sequence similarity.
  • BMP ribonucleoside ABC transporters
  • Example 6 Thl7 memory-recall after ex-vivo stimulation with GAS EVs and recombinant antigens.
  • Example 7 Vaccine candidates identified in GAS EVs are conserved across different M- types.
  • mice were immunized with GAS EVs (30pg of total EV-protein) or recombinantly expressed proteins (5ug of each protein: PrsAl, PrsA2, Spy_1228, GlnP, MtsA, MalX, NIpa/MetQ) formulated with adjuvant (5ug of QS21, 2ug of 3D-MPLA and 50uL of Addavax).
  • GAS EVs (30pg of total EV-protein) or recombinantly expressed proteins (5ug of each protein: PrsAl, PrsA2, Spy_1228, GlnP, MtsA, MalX, NIpa/MetQ) formulated with adjuvant (5ug of QS21, 2ug of 3D-MPLA and 50uL of Addavax).
  • adjuvant 5ug of QS21, 2ug of 3D-MPLA and 50uL of Addavax.
  • the control group received adjuvant alone.
  • mice were anesthetized by isoflurane (Abbott) inhalation and then immunized subcutaneously with lOOpL/mouse of the formulations on days 0 and 14. Fourteen days after the second immunization, serum was collected and antibody titers vs each antigen were measured by ELISA.
  • Streptococcus pyogenes was grown on tryptic soy agar (TSA) plates supplemented with 5% sheep blood at 37°C in a 5% CO2 atmosphere. Liquid cultures were grown statically at 37°C in either Todd-Hewitt broth alone (THB) or supplemented with 0.2% yeast extract (THY). Escherichia coli was grown aerobically in lysogeny broth (LB) at 37°C with constant shaking. When required, E. coli cultures were supplemented with lOOpg/mL spectinomycin or 50pg/mL kanamycin.
  • GAS 5448 AP was grown in THB to an ODeoo of 0.6.
  • Bacteria were pellet by centrifugation at 8000 rpm for 20 minutes, the supernatant was recovered and filtered through a 0.22uM filter (Filtropur S 0.2).
  • Samples were then concentrated 10X with a tangential flow filtration (TFF) capsule (MWCO: lOOkDa, PALL Corporation).
  • EVs were pelleted by ultracentrifugation (30,000 rpm for 4h at 4°C) and further purified using OptiPrep (iodixanol) Density Gradient Medium (Sigma-Aldrich).
  • EV protein concentration was determined using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific). EVs were tested for sterility by spotting on blood agar plates and then stored at -80 until further use.
  • GAS EV particle size and count distribution was measured by dynamic light scattering (DLS) using a Zetasizer Ultra instrument (Malvern Panalytical). Vesicles samples were diluted 1:250 in water and equilibrated for 2 minutes at 25°C before each measurement.
  • DLS dynamic light scattering
  • Cryo-ET data collection and 3D reconstruction Cryo-ET data collection and 3D reconstruction.
  • Cryo-ET data was collected on a 300 kV Krios G3i microscope with a Gatan K3 detector using the Tomo-4 (Thermo Fisher) data collection software. Data was collected at a magnification of x 42,000 and a pixel-size of 2.15 A/px (binned from super-resolution).
  • Single axis tilt-series were collected using a dose-symmetric scheme, with a 3 ° increment from -51 to +51°. Data for each tilt angle was collected as a movie stack of 10 frames and the total dose for each tilt-series was ⁇ 80 e /A 2 . The defocus range for the different tilt-series was between -2 and -6 pm.
  • mice were immunized with GAS EVs and alum (lOpg of total EV-protein and 10 mg/mL aluminum hydroxide -Sigma-Aldrich- in PBS) or alum alone (alum, lOmg/mL in PBS).
  • Mice were anesthetized by isoflurane (Abbott) inhalation and then immunized intranasally with 50pL/mouse of the formulations on days 0 and 14. Seven days after the second immunization, mice were euthanized and nasal washes (in PBS), blood (obtained via heart puncture), spleen and lungs were recovered under aseptic conditions.
  • GAS 5448 AP or different invasive GAS isolates were grown at 37°C in THY to an ODeoo of 0.6.
  • Bacteria were washed 2 times with PBS supplemented with EDTA-free protease inhibitor cocktail (complete, Roche) and heat inactivated at for 2.30h at 60°C.
  • Nunc MaxiSorp plates (Thermo Scientific) were coated with lOOpI of the bacterial suspension (adjusted to an ODeoo of 0.6 in PBS + complete) and incubated overnight at 4°C. Next, plates were blocked for 2h at room temperature with 200pl of 2.5% skim milk in PBS.
  • mice sera (1:500 in PBS)
  • lOOpL of goat anti-mouse IgG-HRP diluted 1:5000 in 1% BSA in PBS.
  • Plates were washed 3 times with PBS after each incubation step.
  • samples were developed with the TMB substrate reagent set (BD OptEIA) for 20 minutes. The reaction was stopped wit 50pL of sulfuric acid 0.5M and the absorbance was measured at 450 and 570nm. For nasal washes, samples were not diluted and incubated overnight.
  • Rabbit anti-mouse IgA-HRP was used at a 1:1000 dilution in 1% BSA in PBS.
  • GAS EVs were prepared as indicated above. Two micrograms of GAS EVs were mixed with IX NuPAGE LDS sample buffer (Invitrogen). For cells lysates, GAS strains were grown in THY to an ODeoo of 0.6. Cells were pelleted by centrifugation, resuspended in PBS and lysed by mechanical disruption. After centrifugation, the cleared cell lysate was recovered and mixed with IX NuPAGE LDS sample buffer (Invitrogen). Samples were boiled for 10 minutes and resolved by SDS-PAGE using 4-12% NuPAGE Bis-Tris protein gels (Invitrogen) and transferred to PVDF (polyvinylidene difluoride) membranes.
  • IX NuPAGE LDS sample buffer Invitrogen
  • Membranes were blocked overnight with 5% skim milk in tPBS (PBS containing 0.1% Tween-20). After three washes with tPBS, membranes were incubated with primary antibodies, either pooled sera from immunized mice (1:5000) or anti-GAPDH (1:20,000). HRP-conjugated antibodies (1:10,000) were used as secondary antibodies. Membranes were developed with Amersham ECL Plus Western blotting detection system (GE Healthcare Life Sciences) using ChemiDoc XRS+ (Bio-Rad Laboratories).
  • Protein G HP SpinTrap/Ab columns were pre-equilibrated with PBS. Protein G Sepharose was removed from the columns and incubated with pooled sera (lOpL sera/400pL PBS) from immunized mice (GAS EVs/alum or PBS/alum). After lh incubation at 37 ⁇ C, samples were centrifuged (100 x g for 1 minute); after removing the supernatant, the pelleted Protein G Sepharose was washed 4 times with PBS. In parallel, 30pg of GAS EVs were solubilized by incubation with Pierce IP lysis buffer (thermo scientific) at 4-C for lh.
  • Coupled Protein G Sepharose was then mixed with solubilized GAS EVs and incubated for 2h at 4 ⁇ C. Finally, Protein G Sepharose was washed 6 times with PBS as described above. Two strategies were employed to elute co-immunoprecipitated proteins: i) coupled Protein G Sepharose was resuspended in IX NuPAGE LDS sample buffer (Novex) and subjected to SDS- PAGE, after 10 minutes, running was stopped, and 1 cm gel slices were cut and used for mass spectrometry, ii) proteins were eluted from Protein G Sepharose with 400pL of 0.1M glycine-HCI, pH 2.7 followed by neutralization with 40pL of IM Tris pH 8.0. Samples were concentrated using SpeedVac (Thermo Fisher) and sent for mass spectrometry.
  • SpeedVac Thermo Fisher
  • GAS EVs samples S. pyogenes EVs were prepared as described in previous sections. Three independent samples, consisting of 30pg of total EVs proteins were sent to mass spectrometry and processed as described above.
  • the soluble region of GlnP (codons 30-520) or the mature form (lacking the signal peptide) of MtsA (codons 22-310), Spy_1228 (BMP, (codons 22-350), PrsAl (codons 24-351), PrsA2 (codons 24-309), Spy_0319 (MetQ, codons 23-281) and MalX (codons 26-419) were cloned into pET28a, which allows the expression of C-terminally 6xHis tagged proteins.
  • glnP, mtsA, BMP, prsAl, prsA2, metQ and malX were amplified from gDNA using primer pairs glnP. fw/glnP.rv, mtsA.fw/mtsA.rv, BMP.fw/BMP.rv, prsAl.fw/prsAl.rv, prsA2.fw/prsA2.rv, metQ.fw/metQ.rv and malX. fw/malX.rv.
  • PCR products were cloned into Ncol/Xhol digested pET28a using the NEBuilder HiFi assembly kit (New England biolabs) according to manufacturer's instructions.
  • BL21 (DE3) (Invitrogen) cells containing the pET28a constructs were cultured in LB containing kanamycin at 37°C with constant shaking until an ODeoo of 0.8 was reached. Then, protein production was induced by the addition of 0.5mM IPTG (isopropyl -D-1 thiogalactopyranoside). Bacterial growth continued for 4h at 30°C, then cells were harvested by centrifugation.
  • IPTG isopropyl -D-1 thiogalactopyranoside
  • Streptococcus pyogenes [1] strains were grown on tryptic soy agar (TSA) plates supplemented with 5% sheep blood at 37°C in a 5% CO2 atmosphere. Liquid cultures were grown statically at 37°C in either Todd- Hewitt broth alone (THB) or supplemented with 0.2% yeast extract (THY). Escherichia coli was grown aerobically in lysogeny broth (LB) at 37°C with constant shaking. When required E. coli cultures, antibiotics were used at the following concentrations: lOOpg/mL spectinomycin or 50pg/mL kanamycin.
  • Marker-less isogenic mutants were generated using the temperature-sensitive plasmid pLZts (Addgene #128799) following previously reported protocols (Barnett, T.C., et al., Genetic Manipulation of Group A Streptococcus-Gene Deletion by Allelic Replacement. Methods Mol Biol, 2020. 2136: p. 59-69).
  • All deletion mutants were generated as follows: ⁇ lkb DNA fragments up- and downstream mtsA, spy_1228, prsAl and prsA2 were amplified by PCR from GAS 5448 gDNA using the following primer pairs: mtsA.up.fw and mtsA.up.rv, mtsA.dn.fw and mtsA.dn.rv, 1228. up. fw and 1228. up.
  • pLZts was amplified by PCR with primers pLZts-S and pLZts-A and used to clone the up- and downstream flanking DNA fragments using the NEBuilder HiFi assembly kit according to manufacturer's instructions. The resulting plasmids were electroporated into GAS 5448 AP cells.
  • Transformants were selected at 30°C on THY agar containing lOOpg/mL spectinomycin. mtsA, spy_1228, prsAl and prsA2 were deleted by allelic replacement.
  • plasmid integration was promoted at 37.5°C in the presences of spectinomycin and then excised at 30°C with no antibiotic selection.
  • Deletion strains were screened by PCR using primer pairs: seq.mtsA.fw and seq.mtsA.rv, seq.1228.fw and seq.1228.rv, seq.prsAl.fw and seq. prsAl. rv, seq.prsA2.fw and seq.prsA2.rv and confirmed by DNA sequencing.
  • Spleens and lungs were collected from mice immunized with GAS EVs/alum or PBS/alum. Lungs were diced into small pieces and digested with DNase (80 U/mL, Sigma) and liberase (0.8 U/mL, Sigma) in HBSS (Sigma) for 45 minutes at 37°C. Digestions were stopped by the addition of lung buffer (2mM EDTA, 2% FBS in PBS). Single lung and spleen-cell suspensions were prepared by homogenizing tissue through a 70 pm cell strainer. Red blood cells (RBCs) were lysed with RBS lysis buffer (BD Pharm).
  • RBS lysis buffer RBS lysis buffer
  • lung cells were stimulated with PMA (Phorbol 12- myristate 13-acetate, 30ng/mL), ionomycin (0.5pg/mL) and Brefeldin A (IX) for 3h at 37°C in a 5% CO2 atmosphere. Samples were then stained with antibodies against surface markers including CD45 (30-F11), CD4 (RM4-5), TCRb (H57-597), CD44 (IM7) in the presence of an Fc Block (Biolegend and ThermoFisher)
  • samples were permeabilized with FOXP3/Transcription factor staining buffer (Invitrogen) for 30 minutes before adding antibodies against IL-17 (TC11-18H10) and I FNy (XMG1.2). Samples were acquired on BD Fortessa or Sony ID700 and analyzed using FlowJo software (Tree Star). Zombie UV fixable dye (Biolegend) was used to exclude dead cells and FMOs were used as gating controls.
  • a total of 2xl0 6 lung cells or splenocytes were stimulated with 0.5pg of GAS EVs, lpg of recombinantly expressed proteins or with media alone. Cells were incubated at 37°C with 5% CO2 for 72 h in restimulation media (see above). After centrifugation, culture supernatants were collected and stored at -20°C before cytokine analysis.
  • IL-17A and I FNy secreted into the culture supernatant was quantified using the mouse IL- 17A (homodimer) or I FNy uncoated ELISA kits (Invitrogen) following manufacturer's instructions. Data are normalized to the media stimulation controls and represented as mean +- SEM Statistical analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition comprenant des vésicules extracellulaires (VE) du Streptococcus pyogenes isolées en suspension dans un véhicule, destinées à être utilisées pour déclencher une réponse immunitaire adaptative contre un streptocoque du groupe A (GAS) chez un sujet. Les VE peuvent comprendre des antigènes MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 et/ou GlnP. L'invention concerne une composition comprenant une ou plusieurs protéines MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 et/ou MalX du S. pyogenes isolées. Les compositions peuvent être utilisées pour induire une immunité protectrice chez un sujet contre une infection à GAS, telle que la pharyngite à streptocoque, la scarlatine, l'impétigo, la méningite à streptocoque, la sinusite à streptocoque, la fasciite nécrosante, la cellulite, le syndrome de choc toxique streptococcique, la fièvre rhumatismale et la glomérulonéphrite post-streptococcique.
PCT/EP2025/070101 2024-07-24 2025-07-14 Immunisation contre le streptocoque du groupe a (gas) Pending WO2026021930A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2430384 2024-07-24
SE2430384-4 2024-07-24

Publications (1)

Publication Number Publication Date
WO2026021930A2 true WO2026021930A2 (fr) 2026-01-29

Family

ID=96432300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/070101 Pending WO2026021930A2 (fr) 2024-07-24 2025-07-14 Immunisation contre le streptocoque du groupe a (gas)

Country Status (1)

Country Link
WO (1) WO2026021930A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018123959A1 (fr) 2016-12-27 2018-07-05 花王株式会社 Procédé de production de cellulose de faible cristallinité, et composition de résine
WO2019051380A1 (fr) 2017-09-08 2019-03-14 Evelo Biosciences, Inc. Vésicules extracellulaires (ev) bactériennes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018123959A1 (fr) 2016-12-27 2018-07-05 花王株式会社 Procédé de production de cellulose de faible cristallinité, et composition de résine
WO2019051380A1 (fr) 2017-09-08 2019-03-14 Evelo Biosciences, Inc. Vésicules extracellulaires (ev) bactériennes

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
AZIZ, R.K ET AL.: "Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB.", MOL MICROBIOL, vol. 51, no. 1, 2004, pages 123 - 34
AZIZ, R.K. ET AL.: "Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB", MOL MICROBIOL, vol. 51, no. 1, 2004, pages 123 - 34
BARNETT, T.C. ET AL.: "Genetic Manipulation of Group A Streptococcus-Gene Deletion by Allelic Replacement", METHODS MOL BIOL, vol. 2136, 2020, pages 59 - 69
CAREY, A. J. ET AL.: "Interleukin-17A contributes to the control of streptococcus pyogenes colonization and inflammation of the female genital tract.", SCI. REP., vol. 6, 2016, pages 26836
CHATELLIER, S. ET AL.: "Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases.", INFECT IMMUN, vol. 68, no. 6, 2000, pages 3523 - 34
CHRISTENSEN, D.MORTENSEN, RROSENKRANDS, I.DIETRICH, J.ANDERSEN, P: "Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses.", MUCOSAL. IMMUNOL., vol. 10, 2017, pages 260 - 270
DARENBERG J ET AL.: "Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden", CLIN INFECT DIS., vol. 45, no. 4, 15 August 2007 (2007-08-15), pages 450 - 8
JANULCZYK RRICCI SBJÖRCK L: "MtsABC is important for manganese and iron transport, oxidative stress resistance, and virulence of Streptococcus pyogenes.", INFECT IMMUN., vol. 71, no. 5, May 2003 (2003-05-01), pages 2656 - 64
MORIKAWA, Y. ET AL.: "Identification and functional analysis of glutamine transporter in Streptococcus mutans", J ORAL MICROBIOL, vol. 12, no. 1, 2020, pages 1797320
MORTENSEN, R. ET AL.: "Local Th17/lgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.", PLOS ONE, vol. 12, 2017
NARCISO ET AL.: "Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA", PROC NATL ACAD SCI U S A., vol. 119, no. 23, 7 June 2022 (2022-06-07)
RESCH ET AL., MBIO, vol. 7, 2016
RIVERA-HERNANDEZ, T. ET AL.: "Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies", MBIO, vol. 11, no. 2, 2020, XP093235070, DOI: 10.1128/mBio.00122-20
SUN, X ET AL.: "Crystal structure and metal binding properties of the lipoprotein MtsA, responsible for iron transport in Streptococcus pyogenes", BIOCHEMISTRY, vol. 48, no. 26, 2009, pages 6184 - 90
SUN, X. ET AL.: "Lipoprotein MtsA of MtsABC in Streptococcus pyogenes primarily binds ferrous ion with bicarbonate as a synergistic anion", FEBS LETT, vol. 582, no. 9, 2008, pages 1351 - 4, XP022587130, DOI: 10.1016/j.febslet.2008.03.020
WALKINSHAW ET AL., VACCINES, vol. 8, 2023, pages 16
WANG, B. ET AL.: "Induction of TGF-betal and TGF-betal-dependent predominant Th17 differentiation by group A streptococcal infection", PROC NATL ACAD SCI U S A, 2010
WU, Z.Y. ET AL.: "Unique virulence role of post-translocational chaperone PrsA in shaping Streptococcus pyogenes secretome.", VIRULENCE, vol. 12, no. 1, 2021, pages 2633 - 2647
YOUSIEF, S.W.M. BAHEY-EL-DINT.I. ZAGHLOUL: "Immunization with the basic membrane protein (BMP) family ABC transporter elicits protection against Enterococcus faecium in a murine infection model.", MICROBES INFECT, vol. 22, no. 3, 2020, pages 127 - 136, XP086137273, DOI: 10.1016/j.micinf.2019.09.002

Similar Documents

Publication Publication Date Title
Olaya-Abril et al. Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae
CN103068838B (zh) 基于重组蛋白的抗链球菌感染疫苗
JP2023123432A (ja) ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒
NZ586367A (en) Improved immunizing composition comprising an antigen from Streptococcus equi
JPH04225924A (ja) ブタ肺疫アクチノバチルス菌のサブユニットワクチン
JP2023503057A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
WO2023067118A1 (fr) Vaccin multivalent d'acinetobacter baumannii déficient en lipopolysaccharides (lps)
JP2025174963A (ja) ヘモフィルス・パラスイスに対する新規ワクチン
KR102922316B1 (ko) 폐렴 구균 표층 단백질
WO2026021930A2 (fr) Immunisation contre le streptocoque du groupe a (gas)
EP2838990A1 (fr) Mycobactérie recombinée codant pour une protéine de fusion hémagglutinine se liant à l'héparine (hbha) et ses utilisations
US20120225079A1 (en) Immunizing composition for reducing streptococcal infections
KR101503907B1 (ko) 흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
US12350324B2 (en) Streptococcal vaccines
CN102448488A (zh) 支原体感染症用疫苗
EP4368633A1 (fr) Flagelline désimmunisée et composition de vaccin la comprenant
US20240033350A1 (en) Lipidated flipr and uses thereof in vaccine
RU2818278C2 (ru) Пневмококковые поверхностные белки
Yu et al. Immunogenicity of the Non-toxic Form of Staphylococcus aureus α-hemolysin using a chimeric fusion in mice
US20210220462A1 (en) Immunogenic proteins and compositions
EP3616717A1 (fr) Anticorps induisant d'antigène recombinant pour la neutralisation de la toxine adénylate cyclase de bordetella
Potocki et al. The combination of recombinant
Locht et al. Pertussis Toxin Improves Immune
HK1183677B (en) Vaccine against streptococcal infections based on recombinant proteins
WO2016149482A2 (fr) Vaccins protéiques cs21 et lnga

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25740826

Country of ref document: EP

Kind code of ref document: A2